Tag Archives: BASI

Top 5 Casino Stocks To Invest In Right Now

Indian benchmark indices fell on Thursday afternoon, with the Nifty50 down 40 points and was trading at 10753 mark while the Sensex shed 103 points, trading at 35930 mark. The fall was largely aided by energy stocks after crude oil prices climbed to their highest in nearly three months.

US West Texas Intermediate (WTI) crude futures were at $54.16 per barrel at 0413 GMT, up 26 cents, or 0.5 percent, from their last settlement. International Brent crude oil futures were up 37 cents, or 0.6 percent, at $63.98 a barrel. China’s crude oil imports in January rose 4.8 percent from a year earlier, customs data showed on Thursday, to an average of 10.03 million barrels per day (bpd), the third straight month that imports have exceeded the 10 million bpd mark.

The global oil market will struggle this year to absorb fast-growing crude supply from outside the Organization of the Petroleum Exporting Countries (OPEC), even with the group’s production cuts and US sanctions on Venezuela and Iran, the International Energy Agency said in a report on Wednesday.

Top 5 Casino Stocks To Invest In Right Now: Bioanalytical Systems, Inc.(BASI)

Bioanalytical Systems, Inc., incorporated on July 17, 1975, is an international contract research organization providing drug discovery and development services and analytical instruments. The Company’s clients and partners include pharmaceutical, biotechnology, academic and government organizations. The Company derives its revenues from sales of its research services and drug development tools. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and biomolecule drug candidates. The Company’s principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the global pharmaceutical companies. The Company operates in two business segments: contract research services and research products, both of which addresses the bioanalytical, preclinical, and clinical research needs of drug developers.

Services

This segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. Product Characterization, Method Development, and Validation: Analytical methods, primarily performed in West Lafayette, Indiana, determine potency, purity, chemical composition, structure, and physical properties of a compound. Bioanalytical Testing: The Company analyzes specimens from preclinical and clinical trials to measure drug and metabolite concentrations in complex biological matrices. Bioanalysis is performed at its facilities in West Lafayette, Indiana. Stability Testing: The Company tests stability of drug substances and formulated drug products, and maintains storage facilities in West Lafayette, Indiana. In Vivo Pharmacology: The Company provides preclinical in vivo sampling services for the continuous monitoring of chemical changes in life, in particular, how a drug enters, travels thr! ough, and is metabolized in living systems. Those services are performed in customized facilities in West Lafayette and Evansville, Indiana using its robotic Culex Automated Pharmacology System. Preclinical and Pathology Services: The Company provides pharmacokinetic and safety testing in studies ranging from acute safety monitoring of drugs and medical devices to chronic, multi-year oncogenicity studies in its Evansville, Indiana site.

Research Products

This segment designs, develops, manufactures, and markets in vivo sampling systems and accessories (including disposables, training, and systems qualification); physiology monitoring tools; and liquid chromatography and electrochemistry instruments platforms. Analytical Products: The analytical products consist of the Company’s liquid chromatographic and electrochemical instruments with associated accessories. The critical component of these products is the Epsilon electrochemical platform. The market is principally academic institutions and industrial research companies. In vivo Sampling Products: The in vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments. These are used by pharmaceutical researchers to dose animals and collect biological samples (blood, bile, urine, microdialysate, feces or any bio-fluid) from the animals. The Culex products offer reduction in test model use and comparable reduction in labor. The line also includes in vivo sampling devices sold to drug developers and medical research centers to assist in the study of various medical conditions, including stroke, depression, Alzheimer’s and Parkinson’s diseases, diabetes, and osteoporosis. Vetronics’ Products: The Vetronics’ products consist of instruments and related software to monitor and diagnose cardiac function (electro-cardiogram), and measure other vital physiological parameters primarily in cats and dogs in veterinary clinics.

The Company competes with Covance, Inc.; Pharmaceut! ical Prod! uct Development, Inc.; Charles River Laboratories, Inc., and Quintiles Transnational Holdings, Inc.

Advisors’ Opinion:

  • [By Max Byerly]

    Headlines about Bioanalytical Systems (NASDAQ:BASI) have been trending positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.5882570492565 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 5 Casino Stocks To Invest In Right Now: The Descartes Systems Group Inc.(DSGX)

The Descartes Systems Group Inc. (Descartes), incorporated on February 1, 2012, is a global provider of federated network and global logistics technology solutions that help its customers make and receive shipments and manage related resources. The Company’s network-based solutions, which primarily consist of services and software, connect people to their trading partners and enable business document exchange (bookings, bills of lading, status messages); regulatory compliance and customs filing; route and resource planning, execution and monitoring; access and leverage global trade and restricted party data; inventory and asset visibility; rate and transportation management, and warehouse operations. Its pricing model allows its customers to purchase its solutions either on a perpetual license, subscription or transactional basis.

The Company’s primary focus is on serving transportation providers (air, ocean and truck modes), logistics service providers (including third-party logistics providers, freight forwarders and customs brokers) and distribution-intensive companies. It operates in the United States, Europe, Middle-East and Africa, Canada and Asia Pacific. It caters to various industries, including transportation and logistics, manufacturing, retail, distribution, business services and public sector. The Company’s solutions include Logistics Technology Platform that fuses the Descartes Global Logistics Network (Descartes GLN); customs and regulatory compliance; routing, mobile and telematics; global logistics network services; transportation management, and broker and forwarder enterprise systems. The Logistics Technology Platform leverages the multimodal logistics community to enable companies to connect and collaborate.

The Descartes Global Logistics Network, as the foundation of the Logistics Technology Platform, manages the flow of data and documents that track and control inventory, assets and people in motion. Descartes’ Logistics Application Suite offers an array! of modular, cloud-based, interoperable Web and wireless logistics management applications. Descartes’ Customs and Regulatory Compliance solutions help to bridge the information gap between trading partners and regulatory authorities to enable cargo security screening, customs declaration filings and compliance across multiple regulatory requirements and industry-sponsored initiatives affecting international transportation. Descartes’ Routing, Mobile and Telematics suite supports the full, closed-loop process associated with route planning, route execution, driver and vehicle performance. This single-integrated platform helps deliver operations by uniting optimized route planning, dispatching and global positioning system (GPS) tracking, mobile applications, vehicle telematics, fleet/driver, compliance and performance analytics.

The Descartes GLN manages data semantics, message delivery, and transformation of data pertaining to regional or global operations and the ability to work across wired and wireless technologies. Descartes Global Logistics Network Services include Document Management Services, Community Services and Connectivity Services. Descartes’ Transportation Management solution capabilities include Carrier Compliance & Rate Management, Transportation Planning and Execution, Dock Scheduling and Yard Management, Freight Audit and Settlement, Visibility, Tracking and Performance Management, and Logistics Flow Control. Descartes’ on-demand Broker and Forwarder Enterprise Systems solutions include Forwarder Back Office, and Brokerage and Declaration Services.

Advisors’ Opinion:

  • [By Logan Wallace]

    Descartes Systems Group Inc (NASDAQ:DSGX) (TSE:DSG) – Research analysts at William Blair upped their Q1 2020 earnings estimates for Descartes Systems Group in a report issued on Thursday, March 7th. William Blair analyst M. Pfau now expects that the technology company will post earnings of $0.15 per share for the quarter, up from their previous forecast of $0.13. William Blair also issued estimates for Descartes Systems Group’s Q2 2020 earnings at $0.16 EPS, Q3 2020 earnings at $0.17 EPS, Q4 2020 earnings at $0.17 EPS, FY2020 earnings at $0.65 EPS, Q1 2021 earnings at $0.18 EPS, Q2 2021 earnings at $0.18 EPS, Q3 2021 earnings at $0.18 EPS, Q4 2021 earnings at $0.20 EPS and FY2021 earnings at $0.75 EPS.

  • [By Motley Fool Transcribing]

    Descartes Systems Group (NASDAQ:DSGX) Q4 2019 Earnings Conference CallMarch 6, 2019 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Descartes Systems Group (NASDAQ:DSGX) (TSE:DSG) last issued its earnings results on Wednesday, November 28th. The technology company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). Descartes Systems Group had a return on equity of 5.88% and a net margin of 11.24%. The business had revenue of $70.00 million for the quarter, compared to analyst estimates of $69.69 million. During the same period last year, the business posted $0.08 EPS. Descartes Systems Group’s revenue was up 12.9% on a year-over-year basis. Equities analysts forecast that Descartes Systems Group Inc will post 0.41 EPS for the current year.

    COPYRIGHT VIOLATION WARNING: “Mackenzie Financial Corp Purchases 278,713 Shares of Descartes Systems Group Inc (DSGX)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at www.tickerreport.com/banking-finance/4163867/mackenzie-financial-corp-purchases-278713-shares-of-descartes-systems-group-inc-dsgx.html.

    About Descartes Systems Group

  • [By Shane Hupp]

    Descartes Systems Group (TSE:DSG) (NASDAQ:DSGX) had its target price upped by research analysts at Industrial Alliance Securities from C$29.00 to C$33.00 in a note issued to investors on Tuesday. Industrial Alliance Securities’ price target would indicate a potential downside of 24.83% from the company’s current price.

Top 5 Casino Stocks To Invest In Right Now: Lipocine Inc.(LPCN)

Marathon Bar Corp. (“Marathon Bar”) was incorporated on October 13, 2011, in the State of Delaware. On July 24, 2013, Marathon Bar and MBAR Acquisition Corp. (“Merger Sub”), a wholly owned subsidiary of Marathon Bar, and Lipocine Operating Inc. (“Lipocine Operating”), a privately held company incorporated in Delaware, executed an Agreement and Plan of Merger (“Merger Agreement”). Pursuant to the Merger Agreement, Merger Sub merged with and into Lipocine Operating and Lipocine Operating was the surviving entity. Additionally, pursuant to the Merger Agreement, Marathon Bar changed its name to Lipocine Inc. The Merger is accounted for as a reverse-merger and recapitalization.

General

We are a specialty pharmaceutical company focused on applying our oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health.   Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Lipocine (LPCN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Casino Stocks To Invest In Right Now: AmTrust Financial Services, Inc.(AFSI)

AmTrust Financial Services, Inc. is a Delaware corporation that was acquired by its principal stockholders in 1998 and began trading on the NASDAQ Global Select Market on November 13, 2006. References to “AmTrust,” the “Company,” “we,” “our,” or “us” in this Annual Report on Form 10-K and in other statements and information publicly disseminated by AmTrust Financial Services, Inc., refer to the consolidated operations of the holding company.
Business Overview
AmTrust underwrites and provides property and casualty insurance products, including workers’ compensation, commercial automobile, general liability and extended service and warranty coverage, in the United States and internationally to niche customer groups that we believe are generally under served within the broader insurance market.
Our business model focuses on achieving superior returns and profit growth with the careful management of risk.   Advisors’ Opinion:

  • [By Stephan Byrd]

    BidaskClub cut shares of AmTrust Financial Services (NASDAQ:AFSI) from a hold rating to a sell rating in a report published on Thursday morning.

    Several other research firms have also issued reports on AFSI. Keefe, Bruyette & Woods reaffirmed a $14.58 rating and set a $14.75 price target on shares of AmTrust Financial Services in a research report on Wednesday, July 18th. Zacks Investment Research raised shares of AmTrust Financial Services from a strong sell rating to a hold rating in a research report on Monday, June 18th. Finally, B. Riley upped their price target on shares of AmTrust Financial Services from $12.00 to $14.75 and gave the stock a neutral rating in a research report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. AmTrust Financial Services has a consensus rating of Hold and an average price target of $14.92.

  • [By Ethan Ryder]

    AmTrust Financial Services Inc (NASDAQ:AFSI) has been given a consensus recommendation of “Hold” by the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.63.

  • [By Logan Wallace]

    A number of firms have modified their ratings and price targets on shares of AmTrust Financial Services (NASDAQ: AFSI) recently:

    8/16/2018 – AmTrust Financial Services was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. 8/9/2018 – AmTrust Financial Services was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 8/7/2018 – AmTrust Financial Services had its price target raised by analysts at B. Riley from $12.00 to $14.75. They now have a “neutral” rating on the stock. 7/31/2018 – AmTrust Financial Services was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating. 7/18/2018 – AmTrust Financial Services was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 7/18/2018 – AmTrust Financial Services had its “$14.58” rating reaffirmed by analysts at Keefe, Bruyette & Woods. They now have a $14.75 price target on the stock. 7/10/2018 – AmTrust Financial Services was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating. 6/18/2018 – AmTrust Financial Services was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “AmTrust has agreed to go private as Evergreen Parent will buy 45% of the company’s stake which Karfunkel-Zyskind Family does not own presently for $2.7 billion. This acquisition will help AmTrust focus on long term growth objective rather than on short term results given it is becoming a private company. AmTrust’s leadership position in commercial small business, expansion of other segments and an impressive inorganic growth story poise it well for growth. It also aims to build an investment portfolio that returns in line with

  • [By Ethan Ryder]

    Keefe, Bruyette & Woods reissued their $14.58 rating on shares of AmTrust Financial Services (NASDAQ:AFSI) in a research report report published on Wednesday. They currently have a $14.75 price target on the insurance provider’s stock.

Top 5 Casino Stocks To Invest In Right Now: Cellectis S.A.(CLLS)

Cellectis develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors for the treatment of cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications. It has strategic alliances with Les Laboratoires Servier SAS to develop and commercialize product candidates targeting leukemia and solid tumors; Pfizer Inc. to generate CAR T-cells in the field of oncology; and The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various types of liquid tumors. Cellectis was founded in 1999 and is based in Paris, France.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Media headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.0875412676142 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

  • [By Stephan Byrd]

    Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.